Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

This update of the 2013 guideline will help ensure:

• Uniform approach to molecular testing
• Improved effectiveness of treatment for patients

2nd Most common cancer in both &

1:15
1:17
Develop lung cancer in a lifetime

26% 25%
Die of lung cancer

New Evidence-based Recommendations:

• Patients with certain biomarkers can benefit from targeted therapy
  • EGFR, ALK, and ROSI testing must be performed on all advance stage lung cancer patients

Review all of the new and updated recommendations

Lindeman NI, Cagle PT, Aisner DL et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology [published online January 22, 2018]. J Mol Diagn. https://doi.org/10.1016/j.jmoldx.2017.11.004


© 2018 CAP, IASLC, AMP. All rights reserved.